
Quarterly ResultNov 5, 2026, 04:15 PM
Vera Therapeutics Q3 Revenue $10.3M; Net Loss $93.7M; TRUTAKNA Launch Underway
AI Summary
Vera Therapeutics announced its third quarter 2026 financial results, reporting $10.3 million in net product revenue for TRUTAKNA, which received accelerated FDA approval in July 2026. The company posted a net loss of $93.7 million ($1.30 per share) for the quarter. Key business updates include the TRUTAKNA launch momentum with approximately 700 Patient Start Forms, the completion of a supplemental Biologics License Application (sBLA) for full approval, and positive final efficacy results from the ORIGIN 3 trial presented at ASN Kidney Week. The company ended the quarter with $384.0 million in cash, cash equivalents, and marketable securities.
Key Highlights
- Vera Therapeutics reported Q3 net product revenue of $10.3 million, compared to $0 in the prior year.
- Q3 net loss was $93.7 million ($1.30/share), compared to a net loss of $80.3 million ($1.26/share) in Q3 2025.
- Research and development expenses decreased to $41.3 million from $56.5 million YoY.
- Selling, general and administrative expenses increased to $61.4 million from $27.5 million YoY.
- Cash, cash equivalents, and marketable securities stood at $384.0 million as of September 30, 2026.
- Completed sBLA submission for full approval of TRUTAKNA in adults with primary IgAN.
- TRUTAKNA U.S. launch generated approximately 700 Patient Start Forms (PSFs) to date.
- ORIGIN 3 final efficacy analysis showed stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression.
Price Impact
More from VERA